Azole phenoxy hydroxyureas as selective and orally active inhibitors of 5-lipoxygenase

Journal of Medicinal Chemistry

Volumn 39, Issue 1, 1996, Pages 237-245

  Malamas, Michael S ^a   Carlson, Richard P ^a   Grimes, David ^a   Howell, Ralph ^a   Glaser, Keith ^a   Gunawan, Iwan ^a   Nelson, James A ^a   Kanzelberger, Mira ^a   Shah, Uresh ^a   Hartman, David A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 AMINO 1 (3 TRIFLUOROMETHYLPHENYL) 2 PYRAZOLINE; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; LEUKOTRIENE B4; LIPOXYGENASE INHIBITOR; UREA DERIVATIVE; ZILEUTON;

ANIMAL MODEL; ARTICLE; DRUG BIOAVAILABILITY; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; GUINEA PIG; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONATE 5-LIPOXYGENASE; BIOLOGICAL AVAILABILITY; BRONCHOCONSTRICTION; GUINEA PIGS; HUMANS; HYDROXYUREA; LEUKOTRIENE B4; LIPOXYGENASE INHIBITORS; MACROPHAGES; MICE; MOLECULAR STRUCTURE; MONOCYTES; OXAZOLES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 0030041194     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950363n     Document Type: Article

References (41)

1. Shimizu, T.; Izumi, T.; Seyama, T.; Tadokor, K.; Rarmark, O.; Samuelsson, B. Characterization of leukotriene synthase from murine mast cells: Evidence for its identity to arachidonate 5-lipoxygenase. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 4275-4179.
2. 4 synthase activities. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 857-861.
3. Maycock, A. L.; Pong, S. S.; Evans, J. F.; Miller, D. K. Biochemistry of the lipoxygenase pathways. In Leukotrienes and Lipoxygenases; Rokach, J., Ed.; Elsiever Science Publishers: New York, 1989; pp 143-208.
4. For recent reviews on the role of leukotrienes in disease states, see: (a) Jones, T. R.; Letts, G.; Chan, C. C.; Davies P. Pharmacology and pathophysiology of leukotrienes. In Leukotrienes and Lipoxygenases: Chemical, Biological, and Clinical Aspects; Rokach, J., Ed.; Elsiever Science Publishers: New York, 1989; pp 309-403. (b) Ford-Hutchinson, A. W. Evidence for the involvement of leukotrienes and other lipoxygenase products in disease states. In Leukotrienes and Lipoxygenases: Chemical, Biological, and Clinical Aspects; Rokach, J., Ed.; Elsiever Science Publishers: New York, 1989; pp 420-420. (c) Masamune, H.; Melvin, L. S., Jr. Novel Applications of leukotriene intervention. Annu. Rep. Med. Chem. 1989, 24, 71-80. (d) Brain, S. D.; Williams, T. J. Leukotrienes and inflammation. Pharmacol. Ther. 1990, 44, 52. (e) Salmon, J. A.; Garland, L. G. Leukotriene antagonists and inhibitors of leukotriene biosynthesis as potential therapeutic agents. Prog. Drug Res. 1991, 37, 9.
5. For recent reviews on the role of leukotrienes in disease states, see: (a) Jones, T. R.; Letts, G.; Chan, C. C.; Davies P. Pharmacology and pathophysiology of leukotrienes. In Leukotrienes and Lipoxygenases: Chemical, Biological, and Clinical Aspects; Rokach, J., Ed.; Elsiever Science Publishers: New York, 1989; pp 309-403. (b) Ford-Hutchinson, A. W. Evidence for the involvement of leukotrienes and other lipoxygenase products in disease states. In Leukotrienes and Lipoxygenases: Chemical, Biological, and Clinical Aspects; Rokach, J., Ed.; Elsiever Science Publishers: New York, 1989; pp 420-420. (c) Masamune, H.; Melvin, L. S., Jr. Novel Applications of leukotriene intervention. Annu. Rep. Med. Chem. 1989, 24, 71-80. (d) Brain, S. D.; Williams, T. J. Leukotrienes and inflammation. Pharmacol. Ther. 1990, 44, 52. (e) Salmon, J. A.; Garland, L. G. Leukotriene antagonists and inhibitors of leukotriene biosynthesis as potential therapeutic agents. Prog. Drug Res. 1991, 37, 9.
6. For recent reviews on the role of leukotrienes in disease states, see: (a) Jones, T. R.; Letts, G.; Chan, C. C.; Davies P. Pharmacology and pathophysiology of leukotrienes. In Leukotrienes and Lipoxygenases: Chemical, Biological, and Clinical Aspects; Rokach, J., Ed.; Elsiever Science Publishers: New York, 1989; pp 309-403. (b) Ford-Hutchinson, A. W. Evidence for the involvement of leukotrienes and other lipoxygenase products in disease states. In Leukotrienes and Lipoxygenases: Chemical, Biological, and Clinical Aspects; Rokach, J., Ed.; Elsiever Science Publishers: New York, 1989; pp 420-420. (c) Masamune, H.; Melvin, L. S., Jr. Novel Applications of leukotriene intervention. Annu. Rep. Med. Chem. 1989, 24, 71-80. (d) Brain, S. D.; Williams, T. J. Leukotrienes and inflammation. Pharmacol. Ther. 1990, 44, 52. (e) Salmon, J. A.; Garland, L. G. Leukotriene antagonists and inhibitors of leukotriene biosynthesis as potential therapeutic agents. Prog. Drug Res. 1991, 37, 9.
7. For recent reviews on the role of leukotrienes in disease states, see: (a) Jones, T. R.; Letts, G.; Chan, C. C.; Davies P. Pharmacology and pathophysiology of leukotrienes. In Leukotrienes and Lipoxygenases: Chemical, Biological, and Clinical Aspects; Rokach, J., Ed.; Elsiever Science Publishers: New York, 1989; pp 309-403. (b) Ford-Hutchinson, A. W. Evidence for the involvement of leukotrienes and other lipoxygenase products in disease states. In Leukotrienes and Lipoxygenases: Chemical, Biological, and Clinical Aspects; Rokach, J., Ed.; Elsiever Science Publishers: New York, 1989; pp 420-420. (c) Masamune, H.; Melvin, L. S., Jr. Novel Applications of leukotriene intervention. Annu. Rep. Med. Chem. 1989, 24, 71-80. (d) Brain, S. D.; Williams, T. J. Leukotrienes and inflammation. Pharmacol. Ther. 1990, 44, 52. (e) Salmon, J. A.; Garland, L. G. Leukotriene antagonists and inhibitors of leukotriene biosynthesis as potential therapeutic agents. Prog. Drug Res. 1991, 37, 9.
8. For recent reviews on the role of leukotrienes in disease states, see: (a) Jones, T. R.; Letts, G.; Chan, C. C.; Davies P. Pharmacology and pathophysiology of leukotrienes. In Leukotrienes and Lipoxygenases: Chemical, Biological, and Clinical Aspects; Rokach, J., Ed.; Elsiever Science Publishers: New York, 1989; pp 309-403. (b) Ford-Hutchinson, A. W. Evidence for the involvement of leukotrienes and other lipoxygenase products in disease states. In Leukotrienes and Lipoxygenases: Chemical, Biological, and Clinical Aspects; Rokach, J., Ed.; Elsiever Science Publishers: New York, 1989; pp 420-420. (c) Masamune, H.; Melvin, L. S., Jr. Novel Applications of leukotriene intervention. Annu. Rep. Med. Chem. 1989, 24, 71-80. (d) Brain, S. D.; Williams, T. J. Leukotrienes and inflammation. Pharmacol. Ther. 1990, 44, 52. (e) Salmon, J. A.; Garland, L. G. Leukotriene antagonists and inhibitors of leukotriene biosynthesis as potential therapeutic agents. Prog. Drug Res. 1991, 37, 9.
9. Knapp, H. R. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N. Engl. J. Med. 1990, 323, 1745-1748.
10. Israel, E.; Dermarkarian, R.; Rosemberg, M.; Sperling, R.; Taylor, G.; Rubin, P. The effects of a lipoxygenase inhibitor on asthma induced by cold dry air. N. Engl. J. Med. 1990, 323, 1740-1744.
11. Laursen, L. S.; Naesdal, J.; Bukhave, K.; Lauritsen, K.; Rask-Madsen, J. Selective 5-lipoxygenase inhibition of ulcerative colitis. Lancet 1990, 335, 683-685.
12. Corey, E. J.; Cashmin, J. R.; Kanther, S. S.; Wright, S. W. Rationally designed, potent competitive inhibitors of leukotriene biosynthesis. J. Am. Chem. Soc. 1984, 106, 1503.
13. Jackson, W. P.; Islip, P. J.; Kneen, G.; Pugh, A.; Wates, P. J. Aeetohydroxamic acids as potent, selective, orally active 5-lipoxygenase inhibitors. J. Med. Chem. 1988, 31, 499.
14. Kerdesky, F. A. J.; Holms, H. H.; Schmidt, S. P.; Dyer, R. D.; Carter, G. W. Eicosatetraenehydroxamates: inhibitors of 5-lipoxygenase. Tetrahedron Lett. 1985, 26, 2143.
15. Summers, J. B.; Mazdiyasni, H.; Holms, J. H.; Ratajczak, J. H.; Dyer, R. D.; Carter, G. W. Hydroxamic acid inhibitors of 5-lipoxygenase. J. Med. Chem. 1987, 30, 574.
16. Summers, J. B.; Gunn, B. P.; Mazdiyasni, H.; Goetze, A. M.; Young, P. R.; Bouska, J. B.; Dyer, R. D.; Brooks, D. W.; Carter, G. W. In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase. J. Med. Chem. 1987, 30, 2121.
17. Summers, J. B.; Gunn, B. P.; Martin, J. G.; Mazdiyasni, H.; Stewart, A. O.; Young, P. R.; Goetze, A. M.; Bouska, J. B.; Dyer, R. D.; Brooks, D. W.; Carter, G. W. Orally active hydroxamic acid inhibitors of leukotriene biosynthesis. J. Med. Chem. 1988, 31, 3.
18. Summers, J. B.; Gunn, B. P.; Martin, J. G.; Martin, M. B.; Mazdiyasni, H.; Stewart, A. O.; Young, P. R.; Bouska, J. B.; Goetze, A. M.; Dyer, R. D.; Brooks, D. W.; Carter, G. W. Structure-activity analysis of a class of orally active hydroxamic acid inhibitors of leukotriene biosynthesis. J. Med. Chem. 1988, 31, 1960.
19. Summers, J. B.; Kim, K. H.; Mazdiyasni, H.; Holms, J. H.; Rtajezyk, J. D.; Stewart, A. O.; Dyer, R. D.; Carter, G. W. Hydroxamic acid inhibitors of 5-lipoxygenase: Quantitative structure-activity relationships. J. Med. Chem. 1990, 33, 992.
20. McMillan, R. M.; Walker, E. R. H. Designing therapeutically effective 5-lipoxygenase inhibitors. Trends Pharmacol. Sci. 1992, 13, 323-330.
21. Dixon, R. A. F.; Diehl, R. E.; Opas, E.; et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990, 343, 282-284.
22. Miller, D. K.; Gillard, J. W.; Vickens, P. J.; et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990, 343, 278-281.
23. Meguro, K.; Fugita, T. Thiazolidinedione Derivatives; Their Production and Use. Eur. Patent 177353, 1986.
24. Hughes, D. L. The Mitsunobu reaction. Organic Reactions; John Wiley & Sons Publishers: New York, 1992; pp 335-656.
25. Turchi, I. J. Oxazoles. Heterocyclic Compounds; John Wiley & Sons Publishers: New York, 1986; pp 1-341.
26. (a) Simiti, I.; Chindris, E. Heterocyclic compounds. Delepine reaction with 2-aryl-4-(chloromethyl)-oxazoles. Arch. Pharm. 1971, 304, 425-429.
27. (b) Brown, K.; Newberry R. A. A novel synthesis of 4-hydroxymethyl-2-phenylthiazole involving an epoxy-2-thiazoline intermediate. Tetrahedron Lett. 1969, 32, 2797.
28. Tawada, H.; Nakata, F.; Sugiyama, Y.; Fujita, T.; Meguro, K. Syntheses and antidiabetic activity of 1,2,4-oxadiazozle derivatives. J. Takeda Res. Lab. 1984, 43, 1-11.
29. Sweeney, F. J.; Eskra, J. D.; Carty, T. J. Development of a system for evaluating 5-lipoxygenase inhibitors using human whole blood. Prostaglandins Leukotrienes Med. 1987, 28, 73-93.
30. For materials and methods of these assays, see: (a) Chang, J.; Lamb, B.; Marinari, L.; Kreft, A. F.; Lewis, A. J. Modulation by hydroxyeicosatetraenoic acids (HETEs) of arachidonic acid metabolism in mouse resident peritoneal macrophages. Eur. J. Pharmacol. 1985, 107, 215-222. (b) Mueller, H. W.; O'Flaherty, J. T.; Wykle, R. L. Biosynthesis of platelet-activating factor in rabbit polymorphonuclear neutrophils. J. Biol. Chem. 1983, 258, 6213-6218. (c) Steinder, S.; Tramposch, K. Assay method for the detection of phospholipase A2 inhibitors. Third International Conference of the Inflammation Research Association, 1986; Abstract No. 96. (d) Grimes, D.; Sturm, R. J.; Marinari, L. R.; Carlson, R. P.; Berkenkorf, J. W.; Musser, J. H.; Kreft, A. F.; Weichman, B. M. WY-50295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity. Eur. J. Pharmacol. 1993, 236, 217-228.
31. For materials and methods of these assays, see: (a) Chang, J.; Lamb, B.; Marinari, L.; Kreft, A. F.; Lewis, A. J. Modulation by hydroxyeicosatetraenoic acids (HETEs) of arachidonic acid metabolism in mouse resident peritoneal macrophages. Eur. J. Pharmacol. 1985, 107, 215-222. (b) Mueller, H. W.; O'Flaherty, J. T.; Wykle, R. L. Biosynthesis of platelet-activating factor in rabbit polymorphonuclear neutrophils. J. Biol. Chem. 1983, 258, 6213-6218. (c) Steinder, S.; Tramposch, K. Assay method for the detection of phospholipase A2 inhibitors. Third International Conference of the Inflammation Research Association, 1986; Abstract No. 96. (d) Grimes, D.; Sturm, R. J.; Marinari, L. R.; Carlson, R. P.; Berkenkorf, J. W.; Musser, J. H.; Kreft, A. F.; Weichman, B. M. WY-50295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity. Eur. J. Pharmacol. 1993, 236, 217-228.
32. For materials and methods of these assays, see: (a) Chang, J.; Lamb, B.; Marinari, L.; Kreft, A. F.; Lewis, A. J. Modulation by hydroxyeicosatetraenoic acids (HETEs) of arachidonic acid metabolism in mouse resident peritoneal macrophages. Eur. J. Pharmacol. 1985, 107, 215-222. (b) Mueller, H. W.; O'Flaherty, J. T.; Wykle, R. L. Biosynthesis of platelet-activating factor in rabbit polymorphonuclear neutrophils. J. Biol. Chem. 1983, 258, 6213-6218. (c) Steinder, S.; Tramposch, K. Assay method for the detection of phospholipase A2 inhibitors. Third International Conference of the Inflammation Research Association, 1986; Abstract No. 96. (d) Grimes, D.; Sturm, R. J.; Marinari, L. R.; Carlson, R. P.; Berkenkorf, J. W.; Musser, J. H.; Kreft, A. F.; Weichman, B. M. WY-50295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity. Eur. J. Pharmacol. 1993, 236, 217-228.
33. For materials and methods of these assays, see: (a) Chang, J.; Lamb, B.; Marinari, L.; Kreft, A. F.; Lewis, A. J. Modulation by hydroxyeicosatetraenoic acids (HETEs) of arachidonic acid metabolism in mouse resident peritoneal macrophages. Eur. J. Pharmacol. 1985, 107, 215-222. (b) Mueller, H. W.; O'Flaherty, J. T.; Wykle, R. L. Biosynthesis of platelet-activating factor in rabbit polymorphonuclear neutrophils. J. Biol. Chem. 1983, 258, 6213-6218. (c) Steinder, S.; Tramposch, K. Assay method for the detection of phospholipase A2 inhibitors. Third International Conference of the Inflammation Research Association, 1986; Abstract No. 96. (d) Grimes, D.; Sturm, R. J.; Marinari, L. R.; Carlson, R. P.; Berkenkorf, J. W.; Musser, J. H.; Kreft, A. F.; Weichman, B. M. WY-50295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity. Eur. J. Pharmacol. 1993, 236, 217-228.
34. McMillan, R. M.; Millest, A. J.; Poudman, K. E.; Taylor, K. E. Evaluation of lipoxygenase inhibitors ex vivo. Proceedings of the British Pharmacological Society, 1986.
35. 4 and other agonists. Br. J. Pharmacol. 1983, 79, 839-848.
36. 4 and other agonists. Br. J. Pharmacol. 1983, 79, 839-848.
37. 4 and other agonists. Br. J. Pharmacol. 1983, 79, 839-848.
38. Still, W. C.; Kahn, M.; Mitra, A. Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution. J. Org. Chem. 1978, 43, 2923.
39. Tawada, H.; Nakata, F.; Sugiyama, Y.; Fujita, T.; Meguro, K. 1,2,4-Oxadiazole. J. Takeda Res. Lab. 1984, 43, 1-11.
40. Goto, Y.; Yamazaki, M.; Hamana, M. Studies on Azole Compounds. Reactions of Oxazole N-Oxides with Phosphoryl Chloride and Acetic Anhydride. Chem. Pharm. Bull. 1971, 19, 2050-2057.
41. Litchfield, S. T.; Wilcoxon, F. A. Simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 1949, 96, 99-113.